We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Serodiagnostic Test Developed for Human Leptospirosis

By LabMedica International staff writers
Posted on 11 Jul 2013
A vertical flow diagnostic test has been developed for the serodiagnosis of human leptospirosis, which is difficult to diagnose because of nonspecific symptoms and concurrent other endemic febrile diseases.

Scientists at the Pasteur Institute of New Caledonia (Noumea, New Caledonia) working with their colleagues at the Pasteur Institute (Paris, France) tested 187 confirmed leptospirosis cases sera. More...
There were 120 from New Caledonia, 38 from mainland France, 29 from French West Indies. Whole killed Leptospira fainei cells were used as the antigen for the test line and purified human immunoglobulin M (IgM) as the control line. The mobile phase was made of gold particles conjugated with goat anti-human IgM. The Microscopic Agglutination Test (MAT) was used as the gold standard with a cut-off titer of equal to or greater than 1:400.

Out of the 187 gold standard positive sera tested, 168 were RDT positive, including 15 RDT with a test line intensity graded as weak. Out of the 221 MAT-negative sera tested, 207 were RDT negative. All 14 RDT positive sera were graded weak and originated from nine healthy blood donors and five patients positive for anti-dengue virus IgM. The RDT sensitivity was 89.8% and the specificity 93.7%. This RDT had satisfactory reproducibility, repeatability, thermal tolerance, and shelf life. The comparison with MAT evidenced the earliness of the RDT to detect seroconversion. The Vertical Flow RDT developed displayed good diagnostic performances when compared with a lateral flow RDT (Leptocheck, Zephyr Biomedicals; Goa, India).

The authors concluded that because leptospirosis is endemic in New Caledonia and French West Indies, they considered both a MAT titer of 1:400 as a gold standard and a 1/400 dilution of the serum for the Vertical Flow RDT for evaluation. They wrote that it is highly probable that the use of a lower dilution of 1/200 or 1/100 would result in both an increased sensitivity and a decreased specificity. The use of the Vertical Flow RDT as an initial screen for leptospiral infections would still allow facilitating the difficult differential diagnosis of leptospirosis. The study was published on June 27, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Pasteur Institute of New Caledonia
Pasteur Institute
Zephyr Biomedicals



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.